To study the clinical study of Longqing Tablets（癃清片）in the treatment of chronic prostatitis with dampness-heat stasis.

A total of 80 patients diagnosed with chronic prostatitis with damp-heat and blood stasis were selected and divided into two groups according to random number table. Forty cases in control group were treated with Tamlosin Hydrochloride Sustained-Release Tablet，and the other 40 cases in study group were treated with Longqing Tablets. The clinical efficacy，chronic prostatitis syndrome score index（NIH-CPSI），urodynamic indexes and prostatic fluid related indexes of the two groups were compared.

The total effective rate of the study group was95.00%，higher than that（77.50%）of the control group，and there was statistical significance（P<0.05）. After treatment，the NIH-CPSIscore of the study group was lower than that of the control group，and the difference was statistically significant（P<0.05）. After treatment，compared with those of the control group，themaximum urine flow rate and maximum bladder volume in the study group were higher，and the changes of residual urine volume and maximum detrusor pressure were lower，and there was statistical significance（P<0.05）. After treatment，the levels of monocyte chemoattractant protein-1（MCP-1），macrophage-stimulating factor（M-CSF），vascular cell adhesion molecule 1（VCAM-1），interleukin-10（IL-10）and C-reactive protein（CRP）in the study group were lower than those in the control group，and the differences were statistically significant（P<0.05）.

After Longqing Tablets treating patients with chronic prostatitis with dampness-heatand blood stasis，the clinical symptoms can be alleviated，the inflammatory response can be effectively reduced and the antibacterial effect is good. It can promote the recovery of the patients，and have high clinical application value.